LEADS BIOLABS-B Shares Surge Over 11%, Marking a 30% Gain in Three Days on ESMO Research News

Stock News07-15

Shares of LEADS BIOLABS-B (09887) have surged by over 11% today, extending a rally that has seen the stock gain more than 30% over the past three trading sessions.

As of the latest update, the stock is up 11.45% to HK$67.15, with a trading turnover of HK$166 million.

Key Developments Driving Momentum

The recent upward movement follows the company's announcement regarding the 2026 European Society for Medical Oncology (ESMO) congress. It has been confirmed that six of its latest research achievements have been selected for presentation.

Notably, this includes two high-profile oral presentations, with the potential for a late-breaking abstract (LBA) to be added in September.

In a separate development, the company announced that LBL-024 for first-line non-small cell lung cancer (1L NSCLC) has been selected for an oral presentation at the World Conference on Lung Cancer (WCLC) scheduled for this September.

Significant Regulatory Progress

Adding to the positive news flow, the company recently disclosed that the new drug application for its core asset, LBL-024, has been granted priority review status.

The company stated that this milestone formally locks in the commercialization timeline for its product, with a clear and anticipated path to market approval.

Concurrently, the company is actively advancing all necessary commercial preparations ahead of the anticipated launch.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175511625?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 14:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175511625","market":"us","top_or_hot":-1,"title":"LEADS BIOLABS-B Shares Surge Over 11%, Marking a 30% Gain in Three Days on ESMO Research News","media":"Stock News","content":"<p>Shares of <b>LEADS BIOLABS-B</b> (<b>09887</b>) have surged by over 11% today, extending a rally that has seen the stock gain more than 30% over the past three trading sessions.<br><br>As of the latest update, the stock is up 11.45% to HK$67.15, with a trading turnover of HK$166 million.<br><br>\n<b>Key Developments Driving Momentum</b><br><br>The recent upward movement follows the company's announcement regarding the 2026 European Society for Medical Oncology (ESMO) congress. It has been confirmed that six of its latest research achievements have been selected for presentation.<br><br>Notably, this includes two high-profile oral presentations, with the potential for a late-breaking abstract (LBA) to be added in September.<br><br>In a separate development, the company announced that LBL-024 for first-line non-small cell lung cancer (1L NSCLC) has been selected for an oral presentation at the World Conference on Lung Cancer (WCLC) scheduled for this September.<br><br>\n<b>Significant Regulatory Progress</b><br><br>Adding to the positive news flow, the company recently disclosed that the new drug application for its core asset, LBL-024, has been granted priority review status.<br><br>The company stated that this milestone formally locks in the commercialization timeline for its product, with a clear and anticipated path to market approval.<br><br>Concurrently, the company is actively advancing all necessary commercial preparations ahead of the anticipated launch.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEADS BIOLABS-B Shares Surge Over 11%, Marking a 30% Gain in Three Days on ESMO Research News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEADS BIOLABS-B Shares Surge Over 11%, Marking a 30% Gain in Three Days on ESMO Research News\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-15 14:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>LEADS BIOLABS-B</b> (<b>09887</b>) have surged by over 11% today, extending a rally that has seen the stock gain more than 30% over the past three trading sessions.<br><br>As of the latest update, the stock is up 11.45% to HK$67.15, with a trading turnover of HK$166 million.<br><br>\n<b>Key Developments Driving Momentum</b><br><br>The recent upward movement follows the company's announcement regarding the 2026 European Society for Medical Oncology (ESMO) congress. It has been confirmed that six of its latest research achievements have been selected for presentation.<br><br>Notably, this includes two high-profile oral presentations, with the potential for a late-breaking abstract (LBA) to be added in September.<br><br>In a separate development, the company announced that LBL-024 for first-line non-small cell lung cancer (1L NSCLC) has been selected for an oral presentation at the World Conference on Lung Cancer (WCLC) scheduled for this September.<br><br>\n<b>Significant Regulatory Progress</b><br><br>Adding to the positive news flow, the company recently disclosed that the new drug application for its core asset, LBL-024, has been granted priority review status.<br><br>The company stated that this milestone formally locks in the commercialization timeline for its product, with a clear and anticipated path to market approval.<br><br>Concurrently, the company is actively advancing all necessary commercial preparations ahead of the anticipated launch.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000252160.HKD","symbol_name":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","start_time":0,"source_url":"","article_id":"1175511625","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175511625","pubTimestamp":1784097144,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of LEADS BIOLABS-B (09887) have surged by over 11% today, extending a rally that has seen the stock gain more than 30% over the past three trading sessions.As of the latest update, the stock...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK1161":"生物科技","KCAI":"KraneShares China Alpha Index ETF","09887":"维立志博-B","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","VXUS":"国际股票ETF-Vanguard","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元"},"translate_title":"受 ESMO 研究消息影响，LEADS BIOLABS-B 股价飙升超过 11%，三天内上涨 30%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"KCAI":1,"09887":1},"content_text":"Shares of LEADS BIOLABS-B (09887) have surged by over 11% today, extending a rally that has seen the stock gain more than 30% over the past three trading sessions.As of the latest update, the stock is up 11.45% to HK$67.15, with a trading turnover of HK$166 million.\nKey Developments Driving MomentumThe recent upward movement follows the company's announcement regarding the 2026 European Society for Medical Oncology (ESMO) congress. It has been confirmed that six of its latest research achievements have been selected for presentation.Notably, this includes two high-profile oral presentations, with the potential for a late-breaking abstract (LBA) to be added in September.In a separate development, the company announced that LBL-024 for first-line non-small cell lung cancer (1L NSCLC) has been selected for an oral presentation at the World Conference on Lung Cancer (WCLC) scheduled for this September.\nSignificant Regulatory ProgressAdding to the positive news flow, the company recently disclosed that the new drug application for its core asset, LBL-024, has been granted priority review status.The company stated that this milestone formally locks in the commercialization timeline for its product, with a clear and anticipated path to market approval.Concurrently, the company is actively advancing all necessary commercial preparations ahead of the anticipated launch.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175511625","isCrawlerRequest":true}